Pharmaceutical Technology

FEBRUARY 3, 2023

With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more. So, we set out to solve some of the problems,” she explains.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Camargo

MAY 2, 2021

Advances in scientific knowledge and growth in the cell and gene therapy space have led to a new and exciting era of medicine for patients, as well as a new motivation for regulators to provide clear, efficient pathways for product developers. Source: Medicines in Development | 2020 Update: Cell and Gene Therapy , PhRMA.

Gene Therapy 155

Gene Therapy Gene Packaging Packaging 155

Drug Discovery World

JANUARY 10, 2023

Our catalog of over 6,500+ primary antibodies, 1,200+ secondary antibodies, and 50+ ELISA kits includes reagents for multiplex IF, flow cytometry, and more in fields including immunology, oncology, and neuroscience. Custom antibody development. Antibody validation.

Antibody 52

Antibody Protein Reagent Scientist 52

Drug Discovery World

MAY 7, 2024

Ultimately, we owe it to patients to work together and come up with new and innovative manufacturing as well as process development approaches to accelerate the development and achieve speed to clinic. RA: In recent years, what improvements have we seen to cell-line engineering for antibodies?

Antibody 59

Antibody Production Manufacturing Engineer 59

Drug Discovery World

FEBRUARY 8, 2023

In AAV therapeutics, empty capsids are those that are not packaged with the therapeutic DNA. Partially-filled capsids may also be present, and contain packaged process-related impurities or truncated genetic material. What makes an ideal AAV analytics tool for process development?

Gene Therapy 52

Gene Therapy Gene Antibody Production 52

Drug Discovery World

JULY 18, 2023

Years of development and fast-paced research have continued to unlock its potential, expanding how CRISPR can be used to treat, detect, and prevent common diseases such as cancer and Covid-19. CRISPR also addresses another limitation in CAR T therapies related to the insufficient quantity and poor quality of autologous T cells.

DNA 98

DNA Genome Genomics RNA 98

Drug Discovery World

MARCH 13, 2023

While there is no silver bullet for increasing the availability of CGTs, improving manufacturing processes that enable their development at scale can help reduce the cost of these treatments and get them to those who need them most. But now, the increased efficiency is likely making drug development cheaper.

Gene Therapy 52

Gene Therapy Gene Manufacturing Development 52